Generic Drug Market in Canada

• Publication date: November 2011

Canada is one of the world’s largest pharmaceutical markets, even though it has a low share of only 3% in global pharma industry. In 2010, generics accounted for more than 57% prescriptions and around 26% sales of the total pharmaceutical market. On the back of factors including patent expiration of branded drugs, growing aging population, and government support through cost reduction measures, it is estimated that the market for generic drugs ...

Canada is one of the world’s largest pharmaceutical markets, even though it has a low share of only 3% in global pharma industry. In 2010, generics accounted for more than 57% prescriptions and around 26% sales of the total pharmaceutical market. On the back of factors including patent expiration of branded drugs, growing aging population, and government support through cost reduction measures, it is estimated that the market for generic drugs will be growing at a CAGR of around 13% during 2011-2014.

According to our latest market research report entitled, “Generic Drug Market in Canada”, the provincial governments are implementing necessary steps to ensure the availability of drugs at an affordable cost. With billion dollars drug patents on the verge of expiry, the generic industry is foreseen to undergo a massive growth in the future. Besides, the government is adopting measures to enhance the supply proportion of generic drugs and rebates offered (to pharmacies) will augment revenue patterns of this industry.

Our report has identified that, neurological disorder therapy has shown an aggressive growth of 7.2% in 2010 over 2009, in terms of total prescription and the amount of prescriptions. However, oncology remained at the top position in terms of hospital sales with CAD 863.4 Million revenue in 2010, whereas the cardiovascular drugs have moved out from the list of top ten sales. Other therapy areas, such as anti-cholesterol agents and hypertension are expected to drive the generics market in Canada in future.

This report was compiled by considering all the requisite ingredients of Canadian generics sector and distinguishes domestic market from other generics market in all possible ways. The Canada generics market constitutes higher prices of generics and lower price erosion, in comparison to the US and most European markets, which makes it a major issue of concern for the government. However, the latest regulatory mechanism clearly shows that the Canadian Government has been adopting measures to ensure optimum generic costs.

“Generic Drug Market in Canada” provides extensive research and objective analysis of the generic drug market in Canada. The report effectively evaluates all the factors that are driving the growth and studies current market trends that will shape the future of the industry. The report also has cited the distribution of the drugs and presented state-wise consumptions to depict a much clear picture of the market. The report also examines the performance of various players in the Canadian pharmaceutical and generic markets. Besides, a number of factors that can prove to be deteriorative for the future growth of market have been discussed in the report.

Generic Drug Industry in Canada

1. Analyst View
2. Macroeconomic and Healthcare Factors
2.1 Macroeconomic Indicators
2.2 Population Profile
2.3 Age Profile
2.4 Healthcare Spending and Infrastructure
3. Market Trends
3.1 More Generic Drugs for Hypertension
3.2 Generics Getting Affordable
3.3 Patent Expiration
4. Generics Market Performance
4.1 Market Size and Growth
4.1.1 Prescriptions
4.1.2 Sales
4.2 By Province/Territories
4.2.1 Drug Consumption
4.2.2 Prescriptions
4.2.3 Sales
4.3 By Distribution
4.3.1 Retail Pharmacies
4.3.2 Hospital Pharmacies
4.3.3 Authorized and Independent Generics
4.3.4 Distribution Channels
4.4 By Disease
4.4.1 Cardiovascular Drugs
4.4.2 Psychotherapeutics
4.4.3 Cholesterol Agents
4.4.4 Neurological Agents
4.4.5 Antidiabetics
5. Regulatory Environment
6. Competitive Landscape
6.1 Market Structure
6.2 Key Players Analysis
6.2.1 Apotex
6.2.2 Teva Canada Ltd. (Novopharm)
6.2.3 Mylan
6.2.4 Pharmascience

List of Figures:

Figure 2-1: Nominal GDP (Billion US$), 2008-2010
Figure 2-2: Consumer Price Index (%), 2010-2014
Figure 2-3: Population (Million), 2010-2014
Figure 2-4: Life Expectancy (Years), 2010-2014
Figure 2-5: Population Breakup by Age Group (%), 2010-2014
Figure 2-6: Per Head Healthcare Spending (US$), 2010-2014
Figure 2-7: Number of Doctors (2010-2014)
Figure 2-8: Number of Hospital Beds (per ‘000 Population), 2010-2014
Figure 4-1: Pharmaceutical Sales (Billion CAD), 2010-2014
Figure 4-2: Prescriptions Dispensed in Branded Drugs Market (Million), 2006-2010
Figure 4-3: Prescriptions Dispensed in Generic Drugs Market (Million), 2006-2010
Figure 4-4: Share of Generic and Branded Drugs by Prescription (2006-2010)
Figure 4-5: Average Retail Price of Generic and Branded Drugs (CAD), 2006-2010
Figure 4-6: Generic Drug Sales (Billion CAD), 2010-2014
Figure 4-7: Branded Drug Sales (Billion CAD), 2010-2014
Figure 4-8: Share of Generic and Branded Drugs by Sales (2010-2014)
Figure 4-9: Branded Drug Sales through Retail Pharmacies (Billion CAD), 2010-2014
Figure 4-10: Generic Drug Sales through Retail Pharmacies (Billion CAD), 2010-2014
Figure 4-11: Share of Generic and Branded Drug Sales through Retail Pharmacies (2010-2014)
Figure 4-12: Branded Drug Sales through Hospital Pharmacies (Billion CAD), 2010-2014
Figure 4-13: Generic Drug Sales through Hospital Pharmacies (Billion CAD), 2010-2014
Figure 4-14: Share of Generic and Branded Drug Sales through Hospital Pharmacies (2010-2014)
Figure 4-15: Share of Independent Generic and Authorized Generic Prescriptions (2005-2008)
Figure 4-16: Generic Drugs Market by Retail and Hospital Sales (%), 2010
Figure 4-17: Cardiovascular Drug Market (Billion CAD), 2010-2014
Figure 4-18: Psychotherapeutics Market (Billion CAD), 2010-2014
Figure 4-19: Cholesterol Agents Market (Billion CAD), 2010-2014
Figure 4-20 Neurological Agents Market (Billion CAD), 2010-2014
Figure 4-21: Number of Diabetes Patients in Age Group 20-79 Years (Million), 2010 & 2030
Figure 4-22: Diabetes Therapy Market (Million CAD), 2010-2014

List of Tables:

Table 3-1: Patent Expiration for Some Hypertension Drugs (2012)
Table 3-2: Patent Expiration of Key Drugs (2012)
Table 4-1: Top Ten Therapy Areas by Prescription (‘000), 2010
Table 4-2: Per Capita Drug Spending of Public and Private Sector by Region (CAD), 2010
Table 4-3: Generic Drug Prescriptions Dispensed by Region (%), 2006-2010
Table 4-4: Generic Drug Sales by Region (%), 2006 & 2010
Table 4-5 Top Ten Therapy Areas by Retail Pharmacy Sales (Billion CAD), 2010
Table 4-6: Number of Retail Pharmacies by Category (2006-2011)
Table 4-7: Top Ten Therapy Areas by Hospital Sales (Million CAD), 2010
Table 6-1: Top Pharmaceutical Companies by Sales (Billion CAD), 2010
Table 6-2: Top Generic Drug Companies by Prescription (Million), 2007
Table 6-3: Top Generic Drug Companies by Sales (Million CAD), 2007
Table 6-4: Apotex - Strengths & Weaknesses
Table 6-5: Teva Canada Ltd. (Novopharm) - Strengths & Weaknesses
Table 6-6: Mylan - Strengths & Weaknesses